TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11055468

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy with beta-blockers and diuretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subgroup analysis in diabetic patients
Number of subjects: 0
Study: 9495994

Group type: EXPERIMENTAL
Intervention: 2% lidocaine 5 ml throat surface anesthesia (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group without lidocaine (n = 40)
Number of subjects: 80
Study: 8153921

Group type: EXPERIMENTAL
Intervention: Beta 2 agonist plus corticosteroid (BA + CS) treatment
Number of subjects: 185

Group type: COMPARATOR
Intervention: Bronchodilators only
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Bronchodilator tests
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Bronchodilator response at the start of the study
Number of subjects: 185
Study: 2873740

Group type: EXPERIMENTAL
Intervention: Dietetic, hygienic, and pharmacologic treatment including hypolipidemic agents (mainly probucol and clofibrate) and antihypertensive drugs (mainly diuretics and beta blockers)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Clofibrate plus probucol
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Treated subjects
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Beta blockers or clofibrate
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Probucol or diuretics
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control subjects (high risk and low risk)
Number of subjects: 1200
Study: 30433830

Group type: EXPERIMENTAL
Intervention: Frail participants (defined as having three or more frailty parameters)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Frail participants
Number of subjects: 902

Group type: COMPARATOR
Intervention: Non-frail participants (defined as having two or fewer frailty parameters)
Number of subjects: 902
Study: 28542391

Group type: EXPERIMENTAL
Intervention: Facility-based personalized maternal nutrition counseling
Number of subjects: 2253

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 2253
Study: 25864104

Group type: EXPERIMENTAL
Intervention: Ombrabulin plus cisplatin (25 mg/m2 plus 75 mg/m2 every 3 weeks)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo plus cisplatin (placebo plus 75 mg/m2 every 3 weeks)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Ombrabulin plus cisplatin
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo plus cisplatin
Number of subjects: 355
Study: 22658401

Group type: EXPERIMENTAL
Intervention: Almorexant (200 mg p.o.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Almorexant (200 mg p.o.) with ethanol (0.6 g/L i.v. ethanol clamp for 5 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ethanol (0.6 g/L i.v. ethanol clamp for 5 h)
Number of subjects: 20
Study: 21768546

Group type: EXPERIMENTAL
Intervention: sirolimus‐ and probucol‐eluting stents
Number of subjects: 3002

Group type: COMPARATOR
Intervention: zotarolimus‐eluting stents
Number of subjects: 3002
Study: 19143675

Group type: EXPERIMENTAL
Intervention: BufferGel (BG; ReProtect Inc., Baltimore, Maryland)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: ACIDFORM (Instead Inc., La Jolla, CA, USA)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Placebo gel (K‐Y Jelly; Personal Products Inc., Raritan, NJ, USA)
Number of subjects: 81
Study: 16397514

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil monotherapy
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/HCTZ double therapy
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/HCTZ/Amlodipine besylate triple therapy
Number of subjects: 179
Study: 15106393

Group type: EXPERIMENTAL
Intervention: Nine-week group cognitive-behavioral therapy (CBT) intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 38
Study: 11358906

Group type: EXPERIMENTAL
Intervention: Interferon therapy (leucocytic interferon alfa, escalating schedule for 12 months)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 72
Study: 9446402

Group type: EXPERIMENTAL
Intervention: Myoelectrical activity measurement using two serosal electrodes in ischaemic bowel
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Resected ischaemic bowel submitted to histological examination
Number of subjects: 26
Study: 8181261

Group type: EXPERIMENTAL
Intervention: Nicotinamide (NCT) 25 mg kg‐1 day‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nicotinamide (NCT) 25 mg kg‐1 day‐1 + Cyclosporin (CyA) 5 mg kg‐1 day‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Insulin only (Control)
Number of subjects: 90
Study: 3063587

Group type: EXPERIMENTAL
Intervention: Magnesium aspartate (Mg 5‐Longoral) at a daily dose of 15 mmol
Number of subjects: 985

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 985
Study: 30476320

Group type: EXPERIMENTAL
Intervention: SNAP intervention training on implementing a policy promoting active recreation (AR)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (standard control)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: SNAP intervention
Number of subjects: 76
Study: 28132971

Group type: EXPERIMENTAL
Intervention: Wearable lumbosacral support
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 121
Study: 26210806

Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Paclitaxel-Eluting Stents (PES)
Number of subjects: 1800
Study: 24021709

Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) diet (60-65% carbohydrates, 20-25% fats)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Moderately Restricted Carbohydrate (MRC) diet (43-47% carbohydrates, 36-40% fats)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 30
Study: 21745006

Group type: EXPERIMENTAL
Intervention: Coherent sentences presented in speech envelope/spectrum noise at varying SNR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anomalous sentences presented in speech envelope/spectrum noise at varying SNR
Number of subjects: 0
Study: 19373653

Group type: EXPERIMENTAL
Intervention: Oblimersen/dexamethasone (N = 110)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Dexamethasone alone (N = 114)
Number of subjects: 224
Study: 16771960

Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg t.i.d. started at admission (group A)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control group (group B) - antibiotics started after demonstration of necrosis
Number of subjects: 215
Study: 15273638

Group type: EXPERIMENTAL
Intervention: One-visit endodontic treatment (including a 10‐min intraappointment dressing with 5% iodine‐potassium‐iodide)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Two-visit endodontic treatment (including an interappointment dressing with calcium‐hydroxide paste)
Number of subjects: 96
Study: 11744449

Group type: EXPERIMENTAL
Intervention: Educational intervention for patients and physicians (mailed newsletters, face-to-face visits, printed manuals, and pamphlets)
Number of subjects: 2402

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 2402

Group type: EXPERIMENTAL
Intervention: Educational intervention for physicians
Number of subjects: 2402

Group type: COMPARATOR
Intervention: Control group (physicians without educational intervention)
Number of subjects: 2402
Study: 9427904

Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 38

Group type: COMPARATOR
Intervention: Formula-feeding
Number of subjects: 38
Study: 7912102

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily for 7 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg twice daily for 7 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of metoprolol with pindolol and propranolol
Number of subjects: 20
Study: 3579530

Group type: EXPERIMENTAL
Intervention: Integrated behavioral therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Traditional physical therapy (Bobath therapeutic exercises)
Number of subjects: 29
Study: 31322732

Group type: EXPERIMENTAL
Intervention: Response-adaptive allocation procedure
Number of subjects: 0
Study: 30587148

Group type: EXPERIMENTAL
Intervention: Combined physical exercise and psychosocial intervention (24 individual physical exercise sessions and 6 psychosocial training sessions for children, 2 for parents)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 68
Study: 27013152

Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Aggressive strategy
Number of subjects: 258
Study: 24727052

Group type: EXPERIMENTAL
Intervention: Commercially available CCA urine-cassette assay
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Experimental CCA urine-cassette assay
Number of subjects: 500

Group type: COMPARATOR
Intervention: Kato-Katz faecal smear method (gold-standard)
Number of subjects: 500
Study: 24325697

Group type: EXPERIMENTAL
Intervention: Laser debulking (LD) + drug-eluting balloon (DEB) angioplasty
Number of subjects: 48

Group type: COMPARATOR
Intervention: Drug-eluting balloon (DEB) angioplasty alone
Number of subjects: 48
Study: 20885017

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day, i.v.) for 10 days starting on day 1 after ischemic stroke
Number of subjects: 60

Group type: COMPARATOR
Intervention: No vitamin C therapy (Control group)
Number of subjects: 60
Study: 18065424

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 30
Study: 21314440

Group type: EXPERIMENTAL
Intervention: Oral combination of desmin (300 mg/day) and troxerutin (300 mg/day) with Centella asiatica (30 mg/day) and Melilotus (160 mg/day) for 14 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study: 15921225

Group type: EXPERIMENTAL
Intervention: dilator spring‐loaded nasal strip
Number of subjects: 150

Group type: COMPARATOR
Intervention: placebo device
Number of subjects: 150
Study: 12351469

Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training plus moderate weight loss (RT & WL group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Moderate weight loss plus a control program (WL group)
Number of subjects: 36
Study: 9872188

Group type: EXPERIMENTAL
Intervention: Intravenous conjugated estrogens (1.25 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7619669

Group type: EXPERIMENTAL
Intervention: Diltiazem 200 mg
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 2694332

Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg b.i.d.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: cimetidine 400 mg b.i.d.
Number of subjects: 60
Study: 868455

Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Estradiol valerate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11600740

Group type: EXPERIMENTAL
Intervention: Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire applied to patients with increasing difficulty in performing activities of daily living
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire applied to patients with stable disease
Number of subjects: 510
Study: 30694962

Group type: EXPERIMENTAL
Intervention: 4-week static stretching (SS) program for the hamstrings (SS intervention group; n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention (control group; n = 15)
Number of subjects: 30
Study: 31443789

Group type: EXPERIMENTAL
Intervention: Voretigene neparvovec-rzyl (VN) gene therapy, 1.5×10^11 vector genomes (vg) per eye, subretinal injection.
Number of subjects: 40
Study: 30261008

Group type: EXPERIMENTAL
Intervention: Metformin (2 × 850 mg) for 7 days
Number of subjects: 18
Study: 26786203

Group type: EXPERIMENTAL
Intervention: Higher protein intake (>30g) at each meal
Number of subjects: 67

Group type: COMPARATOR
Intervention: Traditional weight loss regimen (Control)
Number of subjects: 67
Study: 24725989

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (no laser power)
Number of subjects: 40
Study: 22584629

Group type: EXPERIMENTAL
Intervention: DP + stent
Number of subjects: 58

Group type: COMPARATOR
Intervention: DP
Number of subjects: 58
Study: 20452031

Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg daily for 12 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Depressed patients who remitted
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-depressed controls
Number of subjects: 42
Study: 17666283

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15681939

Group type: EXPERIMENTAL
Intervention: 20 microg/kg rFVIIa
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 80 microg/kg rFVIIa
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 14513291

Group type: EXPERIMENTAL
Intervention: [123I]IPT administration
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (normal adults)
Number of subjects: 15
Study: 10543589

Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 30
Study: 8901178

Group type: EXPERIMENTAL
Intervention: Desflurane (n = 26)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Isoflurane (n = 26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 52

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 52
Study: 1671241

Group type: EXPERIMENTAL
Intervention: Transient ischaemic attacks with a history suggestive of lacunar ischaemia
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Lacunar symptoms
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Cortical infarcts
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Lacunar TIAs
Number of subjects: 606
Study: 6896646

Group type: EXPERIMENTAL
Intervention: 300 mg of allopurinol (1H‐pyrazolo‐(3,4‐d) pyrimidin‐4‐ol) administered orally for 7 days
Number of subjects: 10
Study: 29149793

Group type: EXPERIMENTAL
Intervention: DEMIAN nursing intervention, 2 training days
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 180
Study: 30532258

Group type: EXPERIMENTAL
Intervention: Quantum Trajectories Method (QTM) using MPI technology
Number of subjects: 0
Study: 27417288

Group type: EXPERIMENTAL
Intervention: 0.7 mg/day rhGH for 40 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 24508285

Group type: EXPERIMENTAL
Intervention: Nurse facilitated cognitive behavioural self‐management programme
Number of subjects: 260
Study: 22196131

Group type: EXPERIMENTAL
Intervention: 20 Gy EBRT
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: 44 Gy EBRT
Number of subjects: 247

Group type: COMPARATOR
Intervention: Both 20 Gy and 44 Gy EBRT
Number of subjects: 247
Study: 19762016

Group type: EXPERIMENTAL
Intervention: Computer-assisted learning module
Number of subjects: 242

Group type: COMPARATOR
Intervention: Conventional face-to-face teaching methods
Number of subjects: 242
Study: 17407159

Group type: EXPERIMENTAL
Intervention: Elevated plasma TIMP‐1 levels
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Higher TIMP‐1 plasma levels (analyzed as a continuous variable)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Elevated plasma TIMP‐1 level
Number of subjects: 251
Study: 16223204

Group type: EXPERIMENTAL
Intervention: DHEP lecithin gel (1.3%) applied 5 g t.i.d. for 10 days
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo applied 5 g t.i.d. for 10 days
Number of subjects: 158
Study: 12511851

Group type: EXPERIMENTAL
Intervention: Pegvisomant (Somavert(R))
Number of subjects: 0
Study: 10447627

Group type: EXPERIMENTAL
Intervention: Radiation therapy (600 cGy single dose between 2nd and 4th postoperative day)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Indomethacin (2 x 50 mg per day from 1st to 42nd postoperative day)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 154
Study: 8647478

Group type: EXPERIMENTAL
Intervention: Diabetic group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study: 2233916

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg) every 6 hours for 7 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 535845

Group type: EXPERIMENTAL
Intervention: d-triiodothyronine during a 1000-calorie diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary treatment alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment (diet + d-triiodothyronine)
Number of subjects: 0
Study: 31770148

Group type: EXPERIMENTAL
Intervention: High PEEP (15 cm H2O)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional PEEP (5 cm H2O)
Number of subjects: 48
Study: 30670737

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 10629

Group type: EXPERIMENTAL
Intervention: Body fat percentage
Number of subjects: 10629

Group type: EXPERIMENTAL
Intervention: Basal metabolic rate
Number of subjects: 10629

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 10629

Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 10629

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol
Number of subjects: 10629

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol
Number of subjects: 10629

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 10629

Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 10629

Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 10629

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 10629
Study: 27093128

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment (MBT) adherence and competence
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Therapist interventions directed toward exploring mental states
Number of subjects: 15
Study: 26354540

Group type: EXPERIMENTAL
Intervention: Modified DASH diet rich in plant protein (18% protein, two-thirds plant sources)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Modified DASH diet rich in animal protein (18.4% protein, two-thirds animal sources)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Moderate-protein diet (27% protein, two-thirds animal sources)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy American diet (HAD)
Number of subjects: 62
Study: 25001663

Group type: EXPERIMENTAL
Intervention: Nutraceutical combination (red yeast rice, Silybum marianum, octasonol)
Number of subjects: 134
Study: 23251327

Group type: EXPERIMENTAL
Intervention: 6EH (ethambutol 800 mg and isoniazid 300 mg daily for six months)
Number of subjects: 712

Group type: COMPARATOR
Intervention: 36H (isoniazid 300 mg daily for 36 months)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: 6EH
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: 6EH among TST-positive subjects
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: 6EH and 36H
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Confirmed TB cases
Number of subjects: 712
Study: 18805589

Group type: EXPERIMENTAL
Intervention: High blood pressure
Number of subjects: 41

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 41
Study: 17854338

Group type: EXPERIMENTAL
Intervention: Standard DISP with mandatory vehicle sale, but without electronic monitoring (Group 2)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Standard DISP with electronic monitoring, but without mandatory vehicle sale (Group 3)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Standard DISP without electronic monitoring or mandated vehicle sale (Group 4)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Standard DISP with electronic monitoring and vehicle sales requirements (Group 1)
Number of subjects: 477
Study: 14647955

Group type: EXPERIMENTAL
Intervention: Cocaine (0, 15 or 30 mg/70 kg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active priming injection of cocaine (0, 15 or 30 mg/70 kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12411657

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1728

Group type: COMPARATOR
Intervention: Medical treatment (background risk)
Number of subjects: 1728
Study: 10190775

Group type: EXPERIMENTAL
Intervention: Exercise at 80% VO2max to fatigue (mean 37 min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Exercise at 55% VO2max for 3 hours or to fatigue
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Recovery after prolonged exercise at 55% VO2max
Number of subjects: 18
Study: 7606530

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Normal elderly subjects
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Sinusitis patients
Number of subjects: 240

Group type: COMPARATOR
Intervention: Normal elderly
Number of subjects: 240

Group type: COMPARATOR
Intervention: Alzheimer's disease and sinusitis patients
Number of subjects: 240
Study: 2405784

Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no white noise)
Number of subjects: 40
Study: 6892625

Group type: EXPERIMENTAL
Intervention: Caerulein administered by intravenous drip infusion at 2 nanograms/kg/minute, starting 24 hours after surgery.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving no drugs or manipulation (except nasogastric tube for aspiration and water/electrolyte replenishment).
Number of subjects: 0
Study: 30844808

Group type: EXPERIMENTAL
Intervention: PCI-27483-gemcitabine
Number of subjects: 42

Group type: COMPARATOR
Intervention: gemcitabine alone
Number of subjects: 42